ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

(-)-5-(3-ジメチルアミノ-2-メチルプロピル)-10,11-ジヒドロ-5H-ジベンゾ[b,f]アゼピン

Trimipramine

HCID 5584
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
3564-66-7
標準SMILES
CC(CN(C)C)CN1c2ccccc2CCc2ccccc21
InChIKey
ZSCDBOWYZJWBIY-UHFFFAOYSA-N
分子式
C20H26N2
平均分子量
294.4 g/mol
単同位体質量
294.20959884

概要

Trimipramine is a dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant. It has a role as an antidepressant, a xenobiotic and an environmental contaminant. It is a dibenzoazepine and a tertiary amino compound. It is functionally related to an imipramine.

名称と識別子

優先名称
Trimipramine
IUPAC
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine
現地名
(-)-5-(3-ジメチルアミノ-2-メチルプロピル)-10,11-ジヒドロ-5H-ジベンゾ[b,f]アゼピン
英語名
Trimeproprimin
分子式
C20H26N2
分子量
294.43

名称と別名

trimipramine739-71-9TrimeprimineTrimeproprimineSapilentbeta-MethylimipramineTrimepriminaTrimipraminaTrimipraminum7162 RPIL 6001IL-6001
名称をさらに表示
(-)-5-(3-ジメチルアミノ-2-メチルプロピル)-10,11-ジヒドロ-5H-ジベンゾ[b,f]アゼピンFI-612010645RPSurmontylBrn 1321466Trimeproprimin5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,β-trimethyl-, (-)-5H-Dibenz(B,F)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (-)- (9ci)5H-Dibenz[b,f]azepine, 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-, (-)- (8CI)
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amineRP-71625-(3-(Dimethylamino)-2-methylpropyl)-10,11-dihydro-5H-dibenz(b,f)azepine6S082C9NDT5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine7162-RP10,11-dihydro-N,N,beta-trimethyl-5H-dibenz[b,f]azepine-5-propanamine5-(gamma-Dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine

物性

構造計算による物性補完中

XLogP
5.8
極性表面積
6.5 Ų
水素結合供与体数
0
水素結合受容体数
2
回転可能結合数
4
重原子数
22
形式電荷
0
複雑度
317

実験および物理化学的性質

Drugs · 3 件

DEA NFLIS-Drug Category -> Antidepressants

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals

LogP4.2
Solubility · 2 件

Slightly soluble

2.60e-02 g/L

Human Drugs · 3 件

Antidepressants -> Tricyclic antidepressants (TCA)

Breast Feeding; Lactation; Milk, Human; Antidepressive Agents; Antidepressive Agents, Tricyclic

Pharmaceuticals

Melting Point45 °C
Physical DescriptionSolid
Dissociation Constants · 3 件

9.24

9.24

8.5

Collision Cross Section · 3 件

170.5 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: Antidepressants]

169.17 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

171.2 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H301 (97.8%): Toxic if swallowed [Danger Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P272, P273, P280, P301+P316, P302+P352, P304+P340, P305+P354+P338, P317, P319, P321, P330, P332+P317, P333+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 46 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory Information · 2 件

REACH registered substance: Trimipramine (EC: 212-008-3)

Trimipramine: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Hazard Classes and CategoriesAcute Tox. 3 (97.8%)

毒性情報

Treatment · 1 件

Obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an intravenous line and initiate gastric decontamination. A minimum of six hours of observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at any time during this period, extended monitoring is required. (L1712)

HepatotoxicityIn clinical trials, liver test abnormalities were uncommon in patients taking trimipramine (
Exposure RoutesOral. Rapid absorption

化学と産業

薬理情報

ATC Code · 2 件

N - Nervous system

QN - Nervous system

Protein Binding93%-96% (to plasma proteins)
Pharmacodynamics · 1 件

Trimipramine is a tricyclic antidepressant. It was thought that tricyclic antidepressants work by inhibiting the re-uptake of the neurotransmitters norepinephrine and serotonin by nerve cells. However, this response occurs immediately, yet mood does not lift for around two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. Presynaptic receptors are affected: a1 and b1 receptors are sensitized, a2 receptors are desensitised (leading to increased noradrenaline production). Tricyclics are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain. A precise mechanism for their analgesic action is unknown, but it is thought that they modulate anti-pain opioid systems in the CNS via an indirect serotonergic route. They are also effective in migraine prophylaxis, but not in abortion of acute migraine attack. The mechanism of their anti-migraine action is also thought to be serotonergic.

Mechanism of ActionTrimipramine's mechanism of action differs from other tricyclic antidepressants. Trimipramine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).
Biological Half-Life11-18 hrs
Metabolism/Metabolites · 2 件

Hepatic

Hepatic Half Life: 11-18 hrs

FDA Pharmacological Classification · 6 件

6S082C9NDT

TRIMIPRAMINE

Established Pharmacologic Class [EPC] - Tricyclic Antidepressant

Trimipramine is a Tricyclic Antidepressant.

TRIMIPRAMINE

Tricyclic Antidepressant [EPC]

関連反応

0 件
反応記録を作成
関連する反応はまだありません

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
3564-66-7、3564-75-8、739-71-9
PubChem CID
5584
DTXSID
DTXSID8023715
ChEMBL
CHEMBL644
ChEBI
CHEBI:9738
UNII
6S082C9NDT、9K5931C1H5、QJ9MUH57H8
EC Number
212-008-3
Nikkaji
J53.921J、J6.960D、J86.105G

物理化学的性質

沸点
411.8 · 411.8±44.0 °C(Predicted)
比重(密度)
1.029 · 1.029±0.06 g/cm3(Predicted)
酸解離定数(Pka)
9.38 · 9.38±0.28(Predicted)
Toxicity Summary
Trimipramine's mechanism of action differs from other tricyclic antidepressants. Trimipramine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).
Signs and Symptoms · 1 件

Side effects include agitation, coma, confusion, convulsions, dilated pupils, disturbed concentration, drowsiness, hallucinations, high fever, irregular heart rate, low body temperature, muscle rigidity, overactive reflexes, severely low blood pressure, stupor, vomiting

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
EPA Human Health Benchmarks for Pharmaceuticals · 6 件

Trimipramine

1.2

4.9

Maintenance therapy is in the range of 50 to 150 mg/day trimipramine maleate.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 50 mg/day, Lowest Therapeutic Dose (LTD): 0.6 mg/kg-day, and Screening Dose: 0.0002 mg/kg-day.

30-Jul-20

MeSH Pharmacological Classification · 2 件

Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system.

Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.

Absorption, Distribution and ExcretionRapid absorption
Cellular LocationsMembrane

用途と製造

Uses · 2 件

Use (kg) in Switzerland (2009): >750

For the treatment of depression and depression accompanied by anxiety, agitation or sleep disturbance

Use Classification · 2 件

Pharmaceuticals

Pharmaceuticals -> Nervous System -> Antidepressants